Global weight loss medicines are primarily GLP-1 receptor agonists (and dual agonists), led by semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). These dominate sales (tens of billions USD globally in recent years, with tirzepatide and semaglutide products as top sellers).

India manufactures affordable generic versions (or biosimilars for peptides) of several, especially semaglutide after its patent expiry in India around March 2026. Many Indian companies launched dozens of versions, making them significantly cheaper (often 50-70% lower than originator prices). Tirzepatide generics/biosimilars are not yet widely available in India (patents still limit them), though branded versions exist via partnerships.

Here is a list focused on highest-impact globally popular ones manufactured in India (primarily semaglutide generics, plus liraglutide biosimilars). Details on pack size/strength, brands, and manufacturers are based on recent launches (as of mid-2026).

Semaglutide (GLP-1 agonist) – Highest global sales impact (Wegovy for weight loss, Ozempic/Rybelsus for diabetes with weight loss effects)

• Generic versions widely manufactured and sold in India post-patent expiry. Dozens of brands exist from ~40+ companies. Used for chronic weight management (with diet/exercise) and type 2 diabetes. Injectable (weekly) and oral forms available.
  • Sun Pharmaceutical Industries:
    • Noveltreat (weight loss focus): Prefilled pens in dosages 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL (maintenance dose 2.4 mg weekly). Pack size: Single-dose prefilled pens (one weekly injection per pen). Monthly cost ~₹3,490–7,400 depending on dose.
    • Sematrinity (diabetes/weight loss): Similar injectable dosages (e.g., 2 mg and 4 mg options). Pack size: Prefilled pens for weekly use. Monthly ~₹2,960–4,790. Also oral Rybelsus-like tablets (e.g., 14 mg dosage, pack size often 10 tablets/strip).
  • Dr. Reddy’s Laboratories:
    • Obeda: Dosages 2 mg and 4 mg strengths. Pack size: Prefilled disposable pens (each pen delivers a minimum of 4 weekly doses). Monthly cost ~₹4,200 for both strengths. Launched for type 2 diabetes with weight benefits.
  • Zydus Lifesciences:
    • Semaglyn, Mashema, Alterme: Dosage 15 mg/3 mL cartridge in reusable multi-dose pen. Pack size: Cartridge for multiple doses (flexible dosing). Launched for obesity/diabetes.
  • Other notable (examples from many):
    • Alkem Laboratories (e.g., Semasize, Obesema): Low-priced prefilled injections (dosages starting from 0.25 mg). Pack size: Single-shot prefilled pens/syringes. ~₹1,800/month or less for some.
    • Natco Pharma: Very affordable vials/pens (dosages aligned to standard semaglutide titration, e.g., up to 2.4 mg). Pack size: Vials or pens for monthly use. ~₹1,250/month.
    • Others: Torrent (Sembolic, Semalix), Glenmark, Eris, Lupin (co-markets Zydus), Mankind, etc. — similar dosage ranges (0.25 mg to 2.4 mg weekly) in prefilled pens.

Biosimilars note: Semaglutide generics here are essentially biosimilar-like copies of the peptide; many underwent Indian clinical trials for approval.

Liraglutide (GLP-1 agonist) – Earlier weight loss drug (Saxenda globally; Victoza for diabetes)

• Biosimilars available in India, used for weight management and diabetes (daily injection, typical titration from 0.6 mg to 3.0 mg/day). Less dominant globally now vs. semaglutide/tirzepatide but still relevant.
  • Glenmark Pharmaceuticals: Lirafit – Biosimilar, dosages standard liraglutide (0.6 mg, 1.2 mg, 1.8 mg, up to 3 mg daily). Pack size: Prefilled pens (multi-dose, often 3 mL for multiple daily doses). Significantly cheaper (~70% less than originator; ~$1.20/day). Launched for type 2 diabetes with weight loss effects.
  • Biocon: Developed liraglutide biosimilar (dosages matching originator). Pack size: Standard prefilled pens. Approved in some markets; available or in pipeline for India/exports.

Tirzepatide (Dual GIP/GLP-1 agonist) – Currently one of the top global best-sellers (Zepbound for weight loss, Mounjaro for diabetes)

• Branded versions available in India via partnerships; no widespread generics/biosimilars yet (patents limit full copies; development ongoing by Indian firms like Biocon/Sun for future launch, possibly post-2026/2027). Dosages typically 2.5 mg to 15 mg weekly subcutaneous injection. Pack size: Prefilled pens (single or multi-dose depending on brand).
  • Eli Lilly (with Cipla partnership): Mounjaro or Yurpeak – Injectable for diabetes/weight loss (standard titration schedule).
  • Novo Nordisk (with Emcure): Wegovy/Poviztra (semaglutide, but note tirzepatide context in market) — primarily semaglutide-focused.